Antidepressant-like effect of coadministration of sulpiride and fluvoxamine in mice

European Journal of Pharmacology

Volumn 520, Issue 1-3, 2005, Pages 86-90

  Ago, Yukio ^a   Harasawa, Toshiya ^a   Itoh, Soichi ^a   Nakamura, Shigeo ^a   Baba, Akemichi ^a   Matsuda, Toshio ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Antidepressant; Fluvoxamine; Sulpiride; Tail suspension test; WAY100635

Indexed keywords

FLUVOXAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A ANTAGONIST; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SUSPENSION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FLUVOXAMINE; HINDLIMB SUSPENSION; MALE; MICE; MOTOR ACTIVITY; PIPERAZINES; PYRIDINES; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SULPIRIDE;

EID: 25444456945     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.08.011     Document Type: Article

References (35)

1. 1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex Neuropharmacology 45 2003 1050 1056
2. Y. Ago, S. Nakamura, A. Baba, and T. Matsuda Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex Neuropsychopharmacology 30 2005 43 51
3. F. Artigas, P. Celada, M. Laruelle, and A. Adell How does pindolol improve antidepressant action? Trends Pharmacol. Sci. 22 2001 224 228
4. C. Barbui, and M. Hotopf Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomized controlled trials Br. J. Psychiatry 178 2001 129 144
5. O. Benkert, and F. Holsboer Effect of sulpiride in endogenous depression Acta Psychiatr. Scand. 311 1984 43 48 (Suppl)
6. P. Blier, and R. Bergeron The use of pindolol to potentiate antidepressant medication J. Clin. Psychiatry 59 Suppl 5 1998 16 23
7. 1A receptor antagonist, WAY 100,635, in the rat Neuropharmacology 39 2000 1222 1236
8. 1A receptors does not modify the effect of fluoxetine or 5-hydroxytryptophan on ethanol and food intake in rats Psychopharmacology 134 1997 55 63
9. M.S. Cousins, and L.S. Seiden The serotonin-1A receptor antagonist WAY-100635 modifies fluoxetine's antidepressant-like profile on the differential reinforcement of low rates 72-s schedule in rats Psychopharmacology 148 2000 438 442
10. M.A. Da-Rocha Jr., A.J. Puech, and M.H. Thiebot Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice J. Psychopharmacol. 11 1997 211 218
11. 1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex Eur. J. Pharmacol. 345 1998 41 46
12. I.N. Ferrier Treatment of major depression: is improvement enough? J. Clin. Psychiatry 60 Suppl 6 1999 10 14
13. A. Gobert, A. Dekeyne, and M.J. Millan The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572 Neuropharmacology 39 2000 1608 1616
14. 2C receptors Br. J. Pharmacol. 124 1998 1781 1787
15. 1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor Neuropharmacology 36 1997 461 465
16. 1A receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum J. Pharmacol. Exp. Ther. 291 1999 1227 1232
17. S. Koch, K.W. Perry, and F.P. Bymaster Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat Neuropharmacology 46 2004 232 242
18. W. Maier, and O. Benkert Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies Psychopharmacology 115 1994 495 501
19. M.J. Millan, M. Brocco, S. Veiga, L. Cistarelli, C. Melon, and A. Gobert WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex Eur. J. Pharmacol. 341 1998 165 167
20. 1B receptors Eur. J. Pharmacol. 321 1997 R11 R13
21. 1A receptor antagonists neither potentiate nor inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats Eur. J. Pharmacol. 372 1999 127 134
22. J.C. Nelson A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression Biol. Psychiatry 46 1999 1301 1308
23. M. O'Connor, and H. Silver Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression J. Clin. Psychopharmacol. 18 1998 89 91 (letter)
24. R.B. Ostroff, and J.C. Nelson Risperidone augmentation of selective serotonin reuptake inhibitors in major depression J. Clin. Psychiatry 60 1999 256 259
25. C.E. Renard, A.J. Fiocco, F. Clenet, M. Hascoet, and M. Bourin Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology 159 2001 42 50
26. 1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain Neurosci. Lett. 219 1996 123 126
27. 1A receptor activation increases in vivo dopamine release in rat prefrontal cortex Br. J. Pharmacol. 129 2000 1028 1034
28. G. Serra, A. Forgione, P.S. D'Aquila, M. Collu, W. Fratta, and G.L. Gessa Possible mechanism of antidepressant effect of l-sulpiride Clin. Neuropharmacol. 13 Suppl 1 1990 S76 S83
29. R.C. Shelton, G.D. Tollefson, M. Tohen, S. Stahl, K.S. Gannon, T.G. Jacobs, W.R. Buras, F.P. Bymaster, W. Zhang, K.A. Spencer, P.D. Feldman, and H.Y. Meltzer A novel augmentation strategy for treating resistant major depression Am. J. Psychiatry 158 2001 131 134
30. G. Tanda, E. Carboni, R. Frau, and G. Di Chiara Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology 115 1994 285 288
31. G. Tanda, V. Bassareo, and G. Di Chiara Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat Psychopharmacology 123 1996 127 130
32. 1A receptor antagonists Eur. J. Pharmacol. 357 1998 179 184
33. A.V. Vergoni, A. Forgione, and A. Bertolini Chronic administration of l-sulpiride at non-neuroleptic doses reduces the duration of immobility in experimental models of "depression-like" behavior Psychopharmacology 121 1995 279 281
34. P. Willner The mesolimbic dopamine system as a target for rapid antidepressant action Int. Clin. Psychopharmacol. 12 Suppl 3 1997 S7 S14
35. W. Zhang, K.W. Perry, D.T. Wong, B.D. Potts, J. Bao, G.D. Tollefson, and F.P. Bymaster Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex Neuropsychopharmacology 23 2000 250 262